SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA

Reuters

04 Jun

SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA

SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China (NMPA). The group received approval for its Calcium Gluconate and Sodium Chloride Injection (100ml), primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2540052069"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540052069\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540052069?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-04 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540052069","market":"us","top_or_hot":-1,"title":"SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China (NMPA). The group received approval for its Calcium Gluconate and Sodium Chloride Injection (100ml), primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-04 18:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China (NMPA). The group received approval for its Calcium Gluconate and Sodium Chloride Injection (100ml), primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2460026573.USD","symbol_name":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL6cNSRr:1","article_id":"2540052069","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540052069","pubTimestamp":1749032451,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA. SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China . The group received approval for its Calcium Gluconate and Sodium Chloride Injection , primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC","02005":"石四药集团","BK1191":"制药"},"translate_title":"SSY Group Ltd.的葡萄糖酸钙氯化钠注射液和氯化钾颗粒获得中国国家药监局的监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":0.9},"content_text":"SSY Group Ltd. Receives Regulatory Approval for Calcium Gluconate and Sodium Chloride Injection and Potassium Chloride Granules from China's NMPA\n    \n\n        SSY Group Ltd. has announced a significant development in its product portfolio with the approval for drug production and registration of two products by the National Medical Products Administration of China (NMPA). The group received approval for its Calcium Gluconate and Sodium Chloride Injection (100ml), primarily used for treating acute hypocalcemia, magnesium poisoning, and fluoride poisoning. Additionally, the NMPA approved SSY Group's Potassium Chloride Granules, intended for the treatment and prevention of hypokalemia. This announcement is part of SSY Group's effort to keep shareholders and potential investors informed about its latest business developments.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}